{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 41,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide outlines two distinct clinical trial programs (SEACRAFT-1 and SEACRAFT-2) with specific stages, patient cohorts, and regulatory endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/21",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.95,
        "x": 0.02,
        "y": 0.48
      },
      "kind": "diagram",
      "text": "SEACRAFT-2: NRASm Melanoma (Two-stage Phase 3)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56eff3b5-171b-4db1-9813-33a22ccd054f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "SEACRAFT-1: RAS Q61X (Single-arm Phase 1b)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f6d522a-fd97-43df-a05a-1b8e8659c88b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "* Dose selection informed by data on 400+0.5 and 100+1 from SEACRAFT-2 Stage 1 as well as 200+1 from SEACRAFT-1. Note: Naporafenib dosed on a BID schedule; trametinib dosed on a QD schedule",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2876b07c-4ca1-4338-b7ea-3d96eefa55d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Pivotal Phase 3 and Phase 1b trial designs capitalize on promising efficacy signals and support potential successful registration in multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b640c08c-948b-4fc6-81d1-fd2690fc442b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "Describing the potential benefits of Erasca's pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}